The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4456373?pdf=render |
| _version_ | 1818118953645375488 |
|---|---|
| author | Annkristin Heine Stefanie Andrea Erika Held Solveig Nora Daecke Kati Riethausen Philipp Kotthoff Chrystel Flores Christian Kurts Peter Brossart |
| author_facet | Annkristin Heine Stefanie Andrea Erika Held Solveig Nora Daecke Kati Riethausen Philipp Kotthoff Chrystel Flores Christian Kurts Peter Brossart |
| author_sort | Annkristin Heine |
| collection | DOAJ |
| description | Inhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has recently been approved for second line therapy of metastatic renal cell carcinoma. While there is some evidence that axitinib might interfere with the activation of T cells, not much is known about the effects of axitinib on dendritic cell (DC) phenotype and function. We here show that the addition of axitinib during the final Toll-like receptor-4-induced maturation step of monocyte-derived human DCs results in a reduced DC activation characterized by impaired expression of activation markers and co-stimulatory molecules such as CD80, CD83 and CD86. We further found a decreased secretion of interleukin-12 which was accompanied by reduced nuclear expression of the transcription factor cRel. In addition, we found a dose-dependent reduced activation of p38 and STAT3 in axitinib-exposed DCs, whereas the expression was not affected. The dysfunction of axitinib-exposed DCs was further underlined by their impaired induction of allogeneic T cell proliferation in a mixed lymphocyte reaction assay and inhibition of DC migration. Our results demonstrate that axitinib significantly affects DC differentiation and function primarily via the inhibition of the nuclear factor kappa B signaling pathway leading to impaired T cell activation. This will be of importance for the design of future vaccination protocols and therapeutic approaches aiming at combining different treatment strategies, eg such as programmed death-1 inhibitors with axitinib. |
| first_indexed | 2024-12-11T05:02:30Z |
| format | Article |
| id | doaj.art-d008c41a25464cd3939b97fbd5e24767 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T05:02:30Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d008c41a25464cd3939b97fbd5e247672022-12-22T01:20:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01106e012889710.1371/journal.pone.0128897The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.Annkristin HeineStefanie Andrea Erika HeldSolveig Nora DaeckeKati RiethausenPhilipp KotthoffChrystel FloresChristian KurtsPeter BrossartInhibitors of VEGF receptor (VEGFR) signaling such as sorafenib and sunitinib that are currently used in the treatment of malignant diseases have been shown to affect immunological responses by inhibition of the function of antigen presenting cells and T lymphocytes. The VEGFR-inhibitor axitinib has recently been approved for second line therapy of metastatic renal cell carcinoma. While there is some evidence that axitinib might interfere with the activation of T cells, not much is known about the effects of axitinib on dendritic cell (DC) phenotype and function. We here show that the addition of axitinib during the final Toll-like receptor-4-induced maturation step of monocyte-derived human DCs results in a reduced DC activation characterized by impaired expression of activation markers and co-stimulatory molecules such as CD80, CD83 and CD86. We further found a decreased secretion of interleukin-12 which was accompanied by reduced nuclear expression of the transcription factor cRel. In addition, we found a dose-dependent reduced activation of p38 and STAT3 in axitinib-exposed DCs, whereas the expression was not affected. The dysfunction of axitinib-exposed DCs was further underlined by their impaired induction of allogeneic T cell proliferation in a mixed lymphocyte reaction assay and inhibition of DC migration. Our results demonstrate that axitinib significantly affects DC differentiation and function primarily via the inhibition of the nuclear factor kappa B signaling pathway leading to impaired T cell activation. This will be of importance for the design of future vaccination protocols and therapeutic approaches aiming at combining different treatment strategies, eg such as programmed death-1 inhibitors with axitinib.http://europepmc.org/articles/PMC4456373?pdf=render |
| spellingShingle | Annkristin Heine Stefanie Andrea Erika Held Solveig Nora Daecke Kati Riethausen Philipp Kotthoff Chrystel Flores Christian Kurts Peter Brossart The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. PLoS ONE |
| title | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. |
| title_full | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. |
| title_fullStr | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. |
| title_full_unstemmed | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. |
| title_short | The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. |
| title_sort | vegf receptor inhibitor axitinib impairs dendritic cell phenotype and function |
| url | http://europepmc.org/articles/PMC4456373?pdf=render |
| work_keys_str_mv | AT annkristinheine thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT stefanieandreaerikaheld thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT solveignoradaecke thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT katiriethausen thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT philippkotthoff thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT chrystelflores thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT christiankurts thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT peterbrossart thevegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT annkristinheine vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT stefanieandreaerikaheld vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT solveignoradaecke vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT katiriethausen vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT philippkotthoff vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT chrystelflores vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT christiankurts vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction AT peterbrossart vegfreceptorinhibitoraxitinibimpairsdendriticcellphenotypeandfunction |